All In MedTech

Device Trial Radar · NCT07886281

Humanitarian Evaluation of Spatial Emanators for Malaria Control

Humanitarian Deployment and Operational Evaluation of Long-lasting Spatial Emanators for Malaria Control in Northern South Sudan

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32,584

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2028

Sponsor

Lead sponsor
The Mentor InitiativeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United Nations High Commissioner for Refugees; University of Nevada, Las Vegas
First posted
Oct 21, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall aim of this study is to evaluate the feasibility, implementation, public health effectiveness, durability, acceptability and cost of delivering long-lasting spatial emanators at scale through United Nations High Commissioner for Refugees (UNHCR) humanitarian supply chains and distribution systems in northern South Sudan. Primary objective: To determine whether distribution of Guardian™ long-lasting spatial emanators reduces all-age malaria infection prevalence at 6 months in intervention populations compared with contemporaneous control populations during Phase 1 of the study. Secondary objectives: * Estimate the effect of Guardian™ on indoor and outdoor mosquito biting rate, including female Anopheles landing rates. * Evaluate the feasibility and fidelity of humanitarian delivery through UNHCR supply chains, including timeliness, household coverage, adequacy of units relative to shelter volume, unpacking, correct placement and retention. * Assess acceptability and safety, including user understanding, perceived benefit, barriers to use, product-related concerns and willingness to continue use or receive replacement units. * Assess product durability and performance through field observations of physical integrity and quantitative chemical analysis of retrieved units. * Describe changes in routine health facility malaria indicators and household-reported febrile illness as complementary measures of public health impact. Tertiary and exploratory objectives: * Estimate the cost and cost-efficiency of humanitarian delivery, including cost per unit delivered, household reached, person protected and correctly protected person-month, and estimate cost-effectiveness where supported by effectiveness data. * Examine whether coverage, dose adequacy, correct placement, retention, shelter characteristics, population movement, seasonality and other contextual factors explain heterogeneity in epidemiological or entomological effects. * Compare implementation performance and acceptability across different beneficiary groups (refugee camps, host communities and newly arriving displaced populations). * Integrate epidemiological, entomological, implementation, qualitative, durability and economic findings to inform transition of long-lasting spatial emanators toward routine use as a humanitarian vector control commodity and guide future UNHCR, Ministry of Health and WHO implementation and scale-up decisions.

Conditions

  • Malaria Infection

Interventions

  • Guardian™ long-lasting spatial emanatorsDevice

    Arm Description: Guardian™ (SC Johnson \& Son, Racine, WI, USA) is a long-lasting spatial emanator. The active ingredient is transfluthrin (C15H12Cl2F4O2, 2.5 g/Guardian™, EPA Reg. number 432-1588). Each unit has a mean emanation rate of 4.7 mg/day, with 2 units installed per regular size room (12 m2/30 m3; 9.4 mg/day emanation per room). This intervention is designed to remain efficacious for 12-months upon opening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-age malaria infection prevalence at 6 months following Phase 1 Guardian™ deploymentTime frame: 6 months after Phase 1 Guardian™ deployment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The MENTOR Initiative, Jamjang

    Jamjang, Pariang County, South Sudan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.